Ozempic for PCOS: Off-Label Use, Evidence, Risks, and What Patients Need to Know

Is Ozempic approved for PCOS?

Ozempic's label lists three indications: improving glycemic control in adults with type 2 diabetes; reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1]. PCOS is not among them, so a prescription written for PCOS is off-label.

Weight management is a different semaglutide product. Wegovy is approved under its own application, NDA 215256 [4], and Ozempic itself carries no weight-loss indication [1].

Ozempic has no labeled dose for PCOS. The PCOS evidence described in the reviews and trial on this page is mainly for liraglutide, not semaglutide [2][3]. The trials that support Ozempic's approval enrolled adults with type 2 diabetes [1].

Why would a GLP-1 drug be considered for PCOS at all?

PCOS affects an estimated 10-13% of women of reproductive age and is the most common cause of anovulation worldwide [5]. Insulin resistance is a core feature. A 1997 review by Dunaif describes profound insulin resistance in PCOS, links it in at least 50% of women to excessive serine phosphorylation of the insulin receptor, and notes that insulin acts through its own receptor to increase ovarian and adrenal steroid production and pituitary LH release [6].

Semaglutide is a GLP-1 receptor agonist that slows gastric emptying [1] and reduces appetite through GLP-1 receptors in the brain. It produces large weight loss in adults with obesity. In STEP 1, 1,961 adults without diabetes lost a mean 14.9% of body weight over 68 weeks versus 2.4% on placebo [7]. In STEP 2, semaglutide 2.4 mg was studied for 68 weeks in adults with overweight or obesity and type 2 diabetes [8]. Both trials were built around weight, not PCOS, and STEP 1 used semaglutide 2.4 mg, the Wegovy dose; Ozempic's labeled maximum is 2 mg weekly [1].

What evidence exists in women with PCOS?

The GLP-1 literature in this population is mostly liraglutide, a daily GLP-1 receptor agonist. A 2020 review of those studies reported significant weight loss and testosterone reduction, with mixed results for insulin resistance measures and menstrual patterns [2].

The most direct data are from a 28-woman randomized trial in infertile women with obesity and PCOS: metformin 1,000 mg twice daily alone versus metformin plus liraglutide 1.2 mg daily for 12 weeks before ovarian stimulation for IVF [3]. Weight loss was similar, 7.5 kg with the combination versus 7.0 kg with metformin alone (P=0.246). Pregnancy rate per embryo transfer was 85.7% with the combination versus 28.6% with metformin, and the 12-month cumulative pregnancy rate was 69.2% versus 35.7% [3]. Twenty-eight women is a small base for a general rule, and the drug tested was liraglutide.

A 2019 review of GLP-1 in reproduction described understanding of GLP-1 in reproduction as limited and largely unaddressed in clinical studies, and noted that GLP-1 appears to have anti-inflammatory and anti-fibrotic effects in the gonads and endometrium affected by obesity, diabetes and PCOS [9].

What dose is used off-label?

There is no approved PCOS dosing schedule. The Ozempic label describes starting at 0.25 mg once weekly for 4 weeks, then increasing to 0.5 mg and, when needed, to 1 mg and 2 mg after at least 4 weeks at each preceding dose [1]. The label directs once-weekly injection into the abdomen, thigh or upper arm, on the same day each week, with or without meals, using a different site in the same region each week [1]. The label says to give a missed dose within 5 days and otherwise to skip it [1].

Side effects and label warnings

Gastrointestinal effects dominate. In Ozempic's pooled placebo-controlled trials in type 2 diabetes, nausea occurred in 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg; vomiting in 2.3%, 5% and 9.2%; diarrhea in 1.9%, 8.5% and 8.8%; and any GI reaction in 15.3%, 32.7% and 36.4%. Treatment was stopped for GI reasons in 0.4%, 3.1% and 3.8% respectively, and severe GI reactions occurred in 0% on placebo, 0.4% on 0.5 mg and 0.8% on 1 mg [1].

The boxed warning covers thyroid C-cell tumors. Semaglutide caused dose- and duration-dependent thyroid C-cell tumors in rodents at clinically relevant exposures, and whether it does so in humans is unknown; Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. The label says patients should be told about the symptoms of thyroid tumors (neck mass, trouble swallowing, shortness of breath, persistent hoarseness), and says routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection [1].

Other label warnings include acute pancreatitis (with instruction to discontinue if pancreatitis is suspected), acute gallbladder disease, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or a sulfonylurea, serious hypersensitivity reactions and pulmonary aspiration during general anesthesia or deep sedation [1]. The label says Ozempic is not recommended in patients with severe gastroparesis and lists ileus, intestinal obstruction and severe constipation with fecal impaction as postmarketing reports; it does not state that semaglutide causes gastroparesis [1].

Pregnancy, ovulation and contraception

The Ozempic label says to discontinue in women at least 2 months before a planned pregnancy because of the long washout period [1]. In animal studies, embryofetal mortality, structural abnormalities and growth alterations occurred in rats at clinical exposures, and early pregnancy loss or structural abnormalities in rabbits and monkeys; the label says human pregnancy data are limited and that Ozempic should be used in pregnancy only if the potential benefit justifies the potential risk [1].

The fertility signal in PCOS described above comes from liraglutide, not semaglutide [3].

Semaglutide delays gastric emptying. The Ozempic label says that in clinical pharmacology trials semaglutide did not affect the absorption of oral medicines to a clinically relevant degree, while advising caution with oral drugs [1]. The semaglutide labels carry no oral-contraceptive switching advice [1][11].

What about compounded semaglutide?

Semaglutide is sold as the FDA-approved products Ozempic and Wegovy, and also as compounded product. Compounded semaglutide is not FDA approved, and FDA does not review compounded drugs for safety, effectiveness or quality before marketing [12]. FDA has also reported dosing errors with compounded injectable semaglutide [12].